Artiva Biotherapeutics In... (ARTV)
Artiva Biotherapeutics Statistics
Share Statistics
Artiva Biotherapeutics has 24.29M shares outstanding. The number of shares has increased by null% in one year.
| Shares Outstanding | 24.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | - |
| Failed to Deliver (FTD) Shares | 1.35K |
| FTD / Avg. Volume | 1.85% |
Short Selling Information
The latest short interest is 1.25M, so 5.15% of the outstanding shares have been sold short.
| Short Interest | 1.25M |
| Short % of Shares Out | 5.15% |
| Short % of Float | 31.1% |
| Short Ratio (days to cover) | 17.46 |
Valuation Ratios
The PE ratio is -4.05 and the forward PE ratio is -2.13. Artiva Biotherapeutics's PEG ratio is 0.37.
| PE Ratio | -4.05 |
| Forward PE | -2.13 |
| PS Ratio | 3.35 |
| Forward PS | 1.2 |
| PB Ratio | -0.69 |
| P/FCF Ratio | -2.21 |
| PEG Ratio | 0.37 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Artiva Biotherapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.53, with a Debt / Equity ratio of -0.1.
| Current Ratio | 6.53 |
| Quick Ratio | 6.53 |
| Debt / Equity | -0.1 |
| Total Debt / Capitalization | -11.66 |
| Cash Flow / Debt | -2.8 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.17% and return on capital (ROIC) is 21.19%.
| Return on Equity (ROE) | 0.17% |
| Return on Assets (ROA) | -0.26% |
| Return on Capital (ROIC) | 21.19% |
| Revenue Per Employee | $408,439.02 |
| Profits Per Employee | $-337,756.1 |
| Employee Count | 82 |
| Asset Turnover | 0.32 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 72K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 5.29, so Artiva Biotherapeutics's price volatility has been higher than the market average.
| Beta | 5.29 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 6.74 |
| 200-Day Moving Average | null |
| Relative Strength Index (RSI) | 34.91 |
| Average Volume (20 Days) | 73.2K |
Income Statement
In the last 12 months, Artiva Biotherapeutics had revenue of 33.49M and earned -27.7M in profits. Earnings per share was -2.96.
| Revenue | 33.49M |
| Gross Profit | 33.49M |
| Operating Income | -30.67M |
| Net Income | -27.7M |
| EBITDA | -28.41M |
| EBIT | -30.67M |
| Earnings Per Share (EPS) | -2.96 |
Balance Sheet
The company has 53.5M in cash and 16.91M in debt, giving a net cash position of 36.59M.
| Cash & Cash Equivalents | 53.5M |
| Total Debt | 16.91M |
| Net Cash | 36.59M |
| Retained Earnings | -181.31M |
| Total Assets | - |
| Working Capital | - |
Cash Flow
In the last 12 months, operating cash flow was -47.43M and capital expenditures -3.26M, giving a free cash flow of -50.69M.
| Operating Cash Flow | -47.43M |
| Capital Expenditures | -3.26M |
| Free Cash Flow | -50.69M |
| FCF Per Share | -5.42 |
Margins
Gross margin is 100%, with operating and profit margins of -91.58% and -82.69%.
| Gross Margin | 100% |
| Operating Margin | -91.58% |
| Pretax Margin | -82.48% |
| Profit Margin | -82.69% |
| EBITDA Margin | -84.81% |
| EBIT Margin | -91.58% |
| FCF Margin | -151.34% |
Dividends & Yields
ARTV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -76.68% |
| FCF Yield | -54.06% |
Analyst Forecast
The average price target for ARTV is $21, which is 444% higher than the current price. The consensus rating is "Buy".
| Price Target | $21 |
| Price Target Difference | 444% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | null |
| Piotroski F-Score | null |